RDY & Bio-Thera Ink Deal for JNJ's Stelara/Simponi Biosimilar

Dr. Reddy's Laboratories (RDY) and China-based Bio-Thera Solutions announced that they have entered into commercialization and license agreements for BAT2206, a proposed biosimilar of Johnson & Johnson's (JNJ) Stelara (ustekinumab), and BAT2506, a proposed biosimilar candidate of JNJ's Simponi (golimumab). The impending licensing deal is expected to significantly enhance Dr. Reddy's biosimilar portfolio across emerging markets. By capitalizing on its well-established commercial presence, RDY aims to bridge ...